TITLE:
Immunotherapy With Autologous Dexosomes for Patients With Stage IV Melanoma

CONDITION:
Melanoma

INTERVENTION:
autologous dexosomes loaded with tumor-specific peptides

SUMMARY:

      The objective is to determine the safety and efficacy of dexosome immunotherapy in patients
      with Stage IV malignant melanoma
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        -  Patients with Stage IV metastatic melanoma with 0-1 prior treatments for metastatic
             disease.

          -  All patients must have distant skin, subcutaneous, or nodal metastases (M1a) or lung
             metastases (M1b), measurable disease, normal lactate dehydrogenase levels, and HLA
             type A1, A2, or B35.

          -  Patients must have adequate organ function and an estimated life expectancy of at
             least 3 months.
      
